The creation of a European Health Data Space is one of the six strategic priorities for the newly elected European Commission. The European Health Research and Innovation Cloud (HRIC) will be one of the future cornerstone pieces for this area. HealthyCloud will deliver a Strategic Agenda including a Ready-to-implement Roadmap for the HRIC ecosystem. The Strategic Agenda will incorporate the consolidated feedback of a broad range of stakeholders: the European Commission, the Member States and regional, national, European and international relevant initiatives. These agents will be invited to be part of the HealthyCloud’s Stakeholders’ Forum, designed to facilitate the dialogue among them and the Consortium, and to act as an umbrella to bring together similar efforts in specific domains. HealthyCloud has been organized around four fundamental objectives that cover 1) interactions with stakeholders to ensure their voices are included as part of the Strategic Agenda; 2) the inclusion of Ethical, Legal and Societal aspects in the design of the future HRIC ecosystem; 3) the sustainable access, use and re-use of health-related data considering a progressive adoption of the FAIR principles; and 4) the technological solutions in terms of computational facilities and mechanisms to enable distributed health data analysis across Europe. The project is driven by two real-world use-cases (Cancer and Atrial Fibrillation) to ensure that propositions by domain-specific and technological experts are technically and ethically sound and legally compliant. The ultimate goal is to propose an ecosystem that builds and reinforces the trust of patients and citizens in the use of their health data for research. HealthyCloud is a 30-month project that brings together 21 organizations with broad and yet complementary expertise, including 5 Research Infrastructures (ELIXIR, ECRIN, EATRIS, BBMRI and Euro-BioImaging) and 3 Joint Actions (InfAct, iPAAC and eHAction) related to health research.

Luxembourg, a key player in EuroHPC, is leading Europe in high-performance computing (HPC). Its AI Factory initiative aims to establish a secure, trusted infrastructure for AI development, supported by the AI-optimised supercomputer "MeluXina-AI." This supercomputer, with over 2100 GPU-AI accelerators, is designed to train and fine-tune AI models and integrate seamlessly with other AI Factories across Europe. Luxembourg's strategy, as outlined in its coalition agreement "Strengthening Luxembourg for the Future" (12/2023), focuses on AI, data, and quantum technologies. The government is committed to fostering an agile, trustworthy AI ecosystem involving national and international cooperation. The Luxembourg AI Factory (L-AIF) will provide end-to-end AI services, addressing key challenges for AI adopters and promoting cross-border collaboration. Its unique value proposition includes tailored solutions for start-ups and SMEs, a secure supercomputing platform, high-quality data sets, and comprehensive financial instruments. The L-AIF will focus on sectors like Finance, Space, Cybersecurity, and the Green Economy, leveraging local AI stakeholders and public research expertise. The L-AIF initiative is supported by a consortium of five members: LuxProvide, Luxinnovation, LNDS, LIST, and the University of Luxembourg. These entities will implement and operate the AI infrastructure, engage with private-sector companies, facilitate data access, conduct AI research, and support skill development. Their combined efforts will drive Luxembourg's digital transformation and contribute to Europe's competitive AI landscape

The mission of EOSC-ENTRUST is to create a European network of trusted research environments for sensitive data and to drive European interoperability by joint development of a common blueprint for federated data access and analysis. Countries and institutions have made significant investments in secure and trusted data environments to meet the need for research and policy-driven analysis of sensitive datasets such as people's health and socio-economic status, the habitats of vulnerable species and geo-spatial locations of protected sites. There are now a large number of such secure environments in operation - linked to national centres, individual organisations or specific research communities. This fragmented landscape poses challenges for both users and providers: researchers are faced with a large number of different systems and access procedures; providers need to manage federated access across multiple, potentially incompatible, technology and governance frameworks. EOSC-ENTRUST brings together providers of operational Trusted Research Environments from 15 European countries with a shared goal to implement, validate and promote their capabilities through a common European framework using shared standards and common legal, operational and technical language. This blueprint for interoperability is anchored in the EOSC Interoperability Framework spanning the four dimensions of Legal, Organisational, Technical and Semantic interoperability. EOSC-ENTRUST has identified four driver projects covering Genomics, Clinical trials, Social science, and public-private partnerships to benchmark capabilities, inform blueprint design and demonstrate secure data analysis using federated workflows. Targeted outreach activities will expand this open network with further providers and develop policy papers and guidelines for the full range of stakeholders to create a long-term operational TRE framework within the European Open Science Cloud.

ELIXIR unites Europe’s leading life science organisations in managing and safeguarding the increasing volume of data being generated by publicly funded research. It coordinates, integrates and sustains bioinformatics resources across its 23 Nodes. ELIXIR enables users in academia and industry to access services (databases, software, training, standards, compute) provided through national Nodes. ELIXIR is the ESFRI Landmark for life science data and plays a unique role in the landscape, with millions of users globally, supporting the digital-needs of other ESFRIs and Horizon Europe research projects. Increasingly, life-science data is held at national and institutional centres. Thus, large-scale data analytics requires that researchers can find and analyse data distributed across Europe. The purpose of ELIXIR-STEERS is to build capacity for large-scale, cross-border data analysis and for this capacity to be embedded across member states. ELIXIR-STEERS directly benefit Europe’s life scientists by allowing software and workflows to meet requirements of those using them in national centres. A ‘robust, reproducible and green’ approach to software and workflow provision will ensure that scientists have access to high quality, energy-efficient analysis tools. The project will also develop the crediting and recognition systems for software, supporting improvements to research assessment frameworks. Further, ELIXIR-STEERS supports ELIXIR’s long-term operations by addressing the recommendations of the European Commission and ESFRI on the long-term sustainability of research infrastructures. It will strengthen the operational excellence of ELIXIR’s Nodes; support the training and development of professional and scientific staff in ELIXIR Nodes; expand the membership of ELIXIR to new countries, especially widening countries; enable international collaborations in particular with Latin America and Africa; and stimulate innovation and industry engagement.

The Beyond 1 Million Genomes (B1MG) consortium will establish the support and coordination structure for the European 1+ Million Genomes initiative (1+MG), which is based upon the commitment of 20 European Member States and Norway that have signed the Declaration ‘Towards access to at least 1 million sequenced genomes in the EU by 2022’. Collectively, these countries have committed to establish a cross-border federated network of national genome collections associated with phenotypic data, consented for advancing health and medicine practices across Europe. Europe is uniquely placed to take on this challenge and position itself as a global leader in this field. B1MG will go ‘beyond’ the 1M genome target and ‘beyond’ the 20 signatory countries. The project will collaborate with an array of international initiatives and consult a range of stakeholders to support the creation of a pan-European genome-based health data infrastructure, encompassing data quality and exchange standards, access protocols and legal guidance. Recommendations will be translated to a B1MG maturity level model that provides concrete guidance on the steps required to implement personalised medicine, a healthcare approach that takes into account a person’s genetic make-up, at local, regional and national-scale. Personalised medicine is expected to bring significant socio-economic benefits, including more efficient national health systems. Faster and more accurate diagnosis, the development of pharmacogenomics and advancement of preventative medicine will lead to better health, quality of life of patients and increased life expectancy. This will be captured in a methodology for economic evaluation, forming the basis of future business-cases for implementation in the health sector.